Amedisys Reports Third Quarter 2019 Financial Results and Updates 2019 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amedisys (AMED) Tops Q3 EPS by 26c
October 29, 2019 4:09 PM EDTAmedisys (NASDAQ: AMED) reported Q3 EPS of $1.15, $0.26 better than the analyst estimate of $0.89. Revenue for the quarter came in at $494.6 million versus the consensus estimate of $494.16 million.
GUIDANCE:
Amedisys sees FY2019 EPS of $4.32-$4.39, versus the consensus of $4.15. Amedisys sees... More
